Latest news with #NGS
Hindustan Times
6 hours ago
- Health
- Hindustan Times
ICMR-NIV Pune inaugurates high performance computing facility
PUNE The Indian Council of Medical Research (ICMR) launched its first High Performance Computing (HPC) facility at the ICMR–National Institute of Virology (NIV) Pune on Saturday. The advanced system, named NAKSHATRA, was inaugurated by Dr Rajiv Bahl, secretary of the department of health research and director general of ICMR. The facility has been developed under the Pradhan Mantri Ayushman Bharat Health Infrastructure Mission (PM-ABHIM) as part of a new project called 'High Performance Computing Next Generation Sequencing (NGS) Hub'. It is designed to boost the country's ability to process large volumes of genomic and bioinformatics data—an area that faced challenges during the Covid-19 pandemic due to limited computing resources. Speaking at the inauguration, Dr Bahl praised the institute for its timely and strategic step towards 'Viksit Bharat 2047' vision by strengthening the country's genomic surveillance and data analysis capacity. He highlighted how enhanced computing resources are crucial in preparing for technology driven pandemic preparedness and future public health emergencies. Dr Naveen Kumar, director, ICMR-NIV, emphasized the critical role the HPC cluster will play in supporting rapid, data-driven responses to outbreaks. The newly commissioned HPC cluster features twelve compute nodes, offering a total of 700 cores and 1 petabyte of storage. The infrastructure is tailored to support complex bioinformatics workflows including next-generation sequencing (NGS), transcriptomics, phylogenetics, metagenomics, and structural bioinformatics. Initially, the facility will serve five ICMR institutes across the country, acting as a central repository for sequencing data and extending support to Viral Research and Diagnostic Laboratories (VRDLs) in the near future. This makes the Pune-based institute a critical hub for outbreak investigations and pandemic preparedness, with the potential to accelerate AI-driven drug and vaccine discovery.
Arab Times
a day ago
- Health
- Arab Times
Over 40 stem cell transplants performed for children with blood disorders in Kuwait: Minister
KUWAIT CITY, May 31: Minister of Health Dr. Ahmad Al-Awadhi announced that over 40 stem cell transplants have been successfully conducted in Kuwait for children suffering from thalassemia and sickle cell anemia, with the number expected to grow due to advanced medical capabilities and ongoing government support. Speaking at the opening of the first Arab Conference on Thalassemia and Sickle Cell Anemia Awareness, Dr. Al-Awadhi highlighted Kuwait's significant progress in prevention, particularly through the premarital medical examination program launched in 2009. To date, more than 400,000 tests have been conducted using advanced diagnostic tools, including NGS technology, and a specialized genetic laboratory was established for blood disorder diagnosis. A 2019 scientific study confirmed the program's success, showing a 50% reduction in the risk of hereditary blood disease transmission among those intending to marry. This has led to a marked decline in new cases of thalassemia across all age groups in Kuwait. A new law now requires residents, in addition to citizens, to undergo premarital screening. Dr. Al-Awadhi emphasized the Ministry's commitment to improving patient care, including introducing treatments to manage iron overload from frequent transfusions and supporting alternatives that stimulate red blood cell production. He also announced ongoing efforts to introduce gene therapy for children over 12, with plans to include it in national treatment strategies soon. He stressed that thalassemia affects not only individual health but also families and society, reiterating support for initiatives that enhance awareness, early diagnosis, and quality of life. Conference chairperson Dr. Najat Rouh El-Din noted that the event is a collaboration between the Arab Forum for Thalassemia Societies, the World Thalassemia Organization, and the Kuwait Blood Association. It features over 49 speakers from 13 Arab countries, 10 specialized workshops, and sessions on diagnosis, treatment, and patient support. She highlighted the goal of building Arab cooperation, improving patient quality of life, strengthening prevention, and promoting early diagnosis through knowledge exchange, patient support, and unified health strategies. Dr. Maryam Al-Feely, hematology consultant at Al-Ahmadi Hospital and member of the Kuwait Society of Hematology, said the two-day conference includes activities for patients, medical staff, and the public to raise awareness. She credited the success of the event to the dedicated efforts of all involved and expressed hope for continued Arab collaboration in advancing care for blood disorder patients.
Yahoo
3 days ago
- Business
- Yahoo
Electronic Lab Notebook Market worth US$1.03 billion by 2030 with 7.3% CAGR
DELRAY BEACH, Fla., May 29, 2025 /PRNewswire/ -- The global Electronic Lab Notebook Market, valued at US$0.68 billion in 2024 stood at US$0.72 billion in 2025 and is projected to advance at a resilient CAGR of 7.3% from 2025 to 2030, culminating in a forecasted valuation of US$1.03 billion by the end of the period. The adoption of electronic lab notebooks (ELNs) is driven by the growing emphasis on laboratory digitization, the rising need for efficient data management, and integrated compatibility with advanced technologies. Additionally, the increasing use of ELNs within the life sciences sector is expected to fuel their adoption in the life sciences sector. The expanding role of biobanks is also contributing to this trend, as ELNs offer high efficiency in the storing & management of biobank data. As laboratories continue to automate, ELNs are increasingly replacing traditional paper-based notebooks. Download PDF Brochure: Browse in-depth TOC on "Electronic Lab Notebook Market" 110 - Tables40 - Figures200 - Pages By Based on organization size, the electronic lab notebook market has been segmented into small & medium and large organizations. In 2024, the large organization segment accounted for the largest share of the electronic lab notebook market. The key factors contributing to the growth of this segment include the expanding budgets for R&D activities, expanding healthcare infrastructure, and the rising need for robust & efficient data management systems to comply with stringent regulatory requirements. Large organizations often require ELNs that can integrate seamlessly with existing Laboratory Information Management Systems (LIMS), Electronic Lab Management Systems (ELMS), and other enterprise resource planning (ERP) systems. This integration is crucial for streamlining workflows and enhancing productivity. By end user, the ELN market is segmented into life sciences, agriculture and food & beverage, oil & gas and petrochemicals, chemical industry, environmental research, and other end users. The life sciences division is segmented into pharmaceutical & biotechnology companies, contract service organizations, biobanks & biorepositories, clinical research laboratories, academic research institutes, NGS laboratories, and toxicology laboratories. In 2024, the pharmaceutical & biotechnology companies segment accounted for the largest share of the electronic lab notebook market. The rising demand for data reporting & management software within pharmaceutical & biopharmaceutical companies is a key factor contributing to the increasing adoption of electronic lab notebooks (ELNs). Additionally, the surge in R&D initiatives and the expansion of drug discovery & development activities has amplified the need for ELNs to streamline workflows, improve collaboration, and maintain compliance with regulatory requirements. By geography, the electronic lab notebook market is segmented into regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to grow at the highest CAGR during the forecast period owing to the increasing reliance on companies in India & China to outsource drug development contract services; low manufacturing & labor costs; and the growing focus on lab automation and digitization. Supportive initiatives by the government & other private players in the market for expanding healthcare infrastructure are expected to also provide an impetus for adopting electronic lab notebooks during the forecast period. Request Sample Pages : The prominent players operating in the electronic lab notebook market include Revvity, Inc. (US), Dassault Systèmes (France), Benchling (US), Thermo Fisher Scientific, Inc. (US), Waters Corporation (US), IDBS (US), STARLIMS Corporation (US), LabVantage Solutions Inc. (US), LabLynx, Inc (US), Agilent Technologies, Inc. (US), LabWare (US), Eppendorf SE (Germany), Dotmatics (US), Lab-Ally (US), Labforward GmbH (Germany), and Labii Inc. (US), among others. These companies adopted product/service launches, enhancements, agreements, expansions, partnerships, collaborations, and acquisitions to strengthen their market presence in the electronic lab notebook market. Revvity, Inc (US): Revvity, Inc., is a leading provider of ELN solutions, experiencing consistent growth due to its unique and competitive offerings for customers across several industries. The company's leading cloud-native Electronic Lab Notebook (ELN) seamlessly facilitates collaboration and data capture technology. With integrated features such as ChemDraw and Spotfire, the company expedites innovation across various sectors, including Pharmaceutical & Biotechnology, Chemicals & Materials, and Food, Flavor, and Fragrance industries. Revvity designs future-proof solutions for enhanced collaboration & acceleration of scientific workflows, making it an essential tool across Biology, Chemistry, Formulations, and Analysis. In February 2022, Revvity (US) partnered with TetraScience (US). Through this collaboration, TetraScience provides users with the Revvity Signals Research Suite with vendor-agnostic, configurable, and productized instrument integrations via its Tetra R&D Data Cloud. This partnership aims to improve data interoperability and speed up scientific outcomes. Similar developments in the market are expected to offer the company an impetus for growth in the electronic lab notebook market. Dassault Systèmes (France) Dassault Systèmes provides software solutions & consulting services. Dassault Systèmes offers a comprehensive range of applications & solutions through the 3DEXPERIENCE platform. These tools support various domains such as analytics, design, engineering, manufacturing, scientific research, & supply chain planning. Dassault Systèmes has 290,000 customers and 25 million users across Africa, the Asia Pacific, Europe, Latin America, and North America. Dassault Systèmes has a diverse presence with over 180 offices in 42 countries, including the 3DS Paris Campus in France and the 3DS Boston Campus in the US. Thermo Fisher Scientific, Inc. (US) Thermo Fisher Scientific offers a range of Electronic Laboratory Notebook (ELN) solutions, including Labguru and Core ELN, to support research & data management. The company also integrates ELN functionalities into its broader suite of laboratory informatics solutions, including LIMS (Laboratory Information Management Systems) and data analysis tools. The ELNs Requests module is designed to meet the needs of quality control labs, contract research organizations, service labs, R&D, manufacturing, and logistics teams. Thermo Fisher Scientific focuses on providing customers with a complete, end-to-end solution for data acquisition, storage, and analysis. The company is actively working to integrate LIMS, CDS (Data Collection and Storage), and data interpretation tools onto a single platform using Microsoft technologies. The Labguru ELN module, for instance, enables seamless data exchange, traceability, and streamlined workflows. For more information, Inquire Now! Related Reports: Healthcare Cloud Computing Market Computer Vision in Healthcare Market Healthcare IT Market Healthcare Analytics Market Remote Patient Monitoring Market Get access to the latest updates on Electronic Lab Notebook Companies and Electronic Lab Notebook Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content to download multimedia: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Collaborations for Change: AUA and Pfizer Select Recipients for $1.5 Million Grant Program to Improve Advanced Prostate Cancer Care
BALTIMORE, May 29, 2025 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is excited to announce it has selected seven grant winners to split $1.5 million as part of a collaborative initiative with Pfizer External Research & Grants (ER&G) which is aimed to improve the quality of care for individuals with advanced prostate cancer. Following a joint Request for Proposals (RFP), 23 grant proposals were received from urology and urologic oncology institutions and organizations nationwide. After a rigorous review process, seven innovative projects were awarded grant funding, totaling $1.5 million on behalf of the Pfizer-Astellas Alliance. 'The AUA is proud to once again collaborate with Pfizer in supporting forward-thinking research and education in advanced prostate cancer,' said Mark Gonzalgo, MD, PhD, MBA, chair of education at the AUA. 'This grant initiative continues to foster groundbreaking strategies that address unmet needs in care delivery—from earlier diagnosis to individualized treatment approaches. We commend this year's grant recipients for their commitment to improving outcomes and elevating the standard of care for patients navigating this challenging disease.' Congratulations to the following selected applications: 'Addressing Genomic Disparities in Prostate Cancer: A Quality Improvement Initiative for Equitable Access to Germline and Somatic Testing' – Rohan Garje, MD, Miami Cancer Institute 'Advanced Prostate Cancer Collaboration Advances Rural Equity' – Charles Shelton, MD, The Outer Banks Hospital 'AI-Enhanced Quality Improvement to Optimize Genetic Testing in Advanced Prostate Cancer' – Kenneth Nepple, MD, University of Iowa 'Bridging Gaps in Advanced Prostate Cancer Care: A Quality Improvement Initiative in the Bronx' – Christopher Jakubowski, MD, Montefiore Medical Center 'Boosting Precision: Enhancing Germline and Somatic Testing in Advanced Prostate Cancer' – Guru Sonpavde, MD, AdventHealth Foundation Central Florida 'A Clinical Trial to Address Physician- and Patient-based Barriers to NGS Testing' – Catherine Marshall, MD, MPH, Johns Hopkins University 'Implementing MyNavigator Platform in a High Volume, Rural Advanced Prostate Cancer Practice to Optimize Performance of Multidisciplinary Care Team, Improve Patient Symptom Monitoring, and Collect Real World Data: A Quality Improvement Initiative' – Timothy Richardson, MD, Avident Health, LLC *Pending executed agreements About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 26,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy. CONTACT: Corey Del Bianco American Urological Association 443-689-4033 cdelbianco@
Business Wire
4 days ago
- Business
- Business Wire
Thermo Fisher Scientific Celebrates Precision Oncology Advancement at ASCO 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, will showcase some of the technologies that have helped power precision oncology at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Through poster presentations, abstracts, and an end-to-end presence across oncology diagnostics, clinical trials, and drug development, Thermo Fisher will demonstrate how its integrated solutions – from biomarker discovery to commercialization – are improving access to targeted cancer therapies. By advancing NGS technologies that prioritize speed, accuracy, and accessibility, the company, through its clinical sequencing business, is helping to ensure that patients in all care settings benefit from the latest innovations. This year marks a significant milestone for Thermo Fisher: a decade of pharma partnership in NGS companion diagnostics development and commercialization, supporting new drug launches globally with decentralized in-country CDx solution. This commitment extends to its clinical research capabilities. Over the past five years, Thermo Fisher has supported more than 750 hematology and oncology clinical trials, involving over 175,000 patients at more than 35,000 sites in over 100 countries. Through its PPD™ clinical research business, the company takes a patient-centered approach to trial design and execution, ensuring that studies are not only scientifically rigorous but also more accessible and inclusive. 'Reflecting on the last decade of partnership with pharmaceutical companies and their therapeutic innovations, we're proud to continue our legacy as a trusted partner and celebrate the impact these collaborations have had on expanding access to precision cancer care,' said Kathy Davy, president of Clinical Next-Generation Sequencing at Thermo Fisher Scientific. 'Behind every test is a patient waiting for answers. That's what drives us – equipping clinicians with fast, reliable insights so they can make confident, timely treatment decisions that change lives.' Davy will deliver opening remarks at the Canadian Evening at ASCO 2025, hosted by Breast Cancer Canada. Held Friday, May 30, at the Marriott Marquis Chicago, this event brings together researchers, clinicians, advocates, and industry leaders to celebrate progress in cancer research. Research and Abstract Highlights at ASCO 2025 At ASCO 2025, researchers from Thermo Fisher and its customers will present new data on precision oncology, including: Assessment of Homologous Recombination Deficiency and BRCA Status (Abstract 3130, Poster presentation) - evaluates a decentralized NGS assay for identifying HRD and BRCA mutations in ovarian cancer. Combined Genomic Profiling of cfDNA and ctDNA – demonstrates how dual analysis of cfDNA and ctcDNA using a prostate cancer-specific panel can provide complementary molecular insights. Association between Targeted Therapy and Survival in Patients with AML (Abstract e23283 in collaboration with EVERSANA) - analyzes real-world data showing improved survival in high-risk MDS patients receiving targeted therapies based on genetic mutations. Attendees can connect with Thermo Fisher experts at booth #12049 to learn more about how the company supports oncology programs from research through commercialization. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit
